More than 6000 ADHD patients to benefit from new drug funding
Pharmac is funding new medicine for people with ADHD and narcolepsy, and removing the renewal criteria for funded treatments.
nzcity.co.nz3d
A huge boost for New Zealanders with Attention Deficit Hyperactivity Disorder
Pharmac has announced it'll fund new stimulant medicine lisdexamfetamine from December. The medicine -- branded as Vyvanse -- is taken once a day. Chief medical officer, David Hughes, says it's a ...
Pharmac to fund new ADHD medicine
Pharmac is funding new medicine for people with attention deficit hyperactivity disorder (ADHD) and narcolepsy, and removing ...
Pharmac Funds New Medicine And Removes Renewal Criteria For ADHD And Narcolepsy Treatments
From 1 December 2024, Pharmac is also removing the renewal criteria for methylphenidate, dexamfetamine and modafinil, medicines used to treat ADHD and narcolepsy. This means that once an initial ...